AbbVie’s 2Q previews future growth drivers

New sales figures from AbbVie's 2Q19 earnings report gave investors a glimpse into the launch trajectories of drugs the pharma is relying upon to replace lost sales of Humira after the blockbuster begins to face U.S. biosimilar competition in 2023.

Despite global sales of

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers